Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Change in Directorate

On the basis of the recommendations of Nomination & Remuneration Committee in its meeting held today, the Board of Directors have co-opted Dr. Pavan Ganapati Bhat (DIN: 09691260) as an Additional Director and appointed him as an Executive Director i.e., Director & Executive Vice President (Technical Operations) of the Company for a period of 2 (two) years w.e.f. 9th August, 2022 subject to approval of the members of the Company at the ensuing Annual General Meeting. Brief Profile of Dr. Pavan Ganapati Bhat, in terms of the SEBI Listing Regulations, is annexed herewith as Annexure - 1.
09-08-2022
Bigul

NATCO PHARMA LTD. - 524816 - Record Date

Record Date for payment of Interim Dividend for FY 2022-23 is 22nd August, 2022
09-08-2022
Bigul

NATCO PHARMA LTD. - 524816 - Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Interim Dividend

Unaudited Financial Results for the Quarter ended 30th June, 2022 and Interim Dividend of Rs.3.50 per equity share of Rs.2/- each
09-08-2022
Bigul

NATCO PHARMA LTD. - 524816 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended 30Th June, 2022 And Interim Dividend

Unaudited Financial Results for the Quarter ended 30th June, 2022 and Interim Dividend of Rs.3.50 per equity share of Rs.2/- each
09-08-2022
Bigul

NATCO PHARMA LTD. - 524816 - Board Meeting Intimation for Consideration Of Unaudited Financial Results And Interim Dividend For FY 2022-23, If Any

NATCO PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2022 ,inter alia, to consider and approve consideration of unaudited Financial Results and Interim Dividend for FY 2022-23, if any
01-08-2022
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution (generic for Jevtana Kit(r))
25-07-2022
Bigul

NATCO PHARMA LTD. - 524816 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Compliances Certificate under Regulation 74(5) of SEBI(DP) Regulations for the quarter ending 30th June, 2022
04-07-2022
Bigul

NATCO PHARMA LTD. - 524816 - Statement Of Investor Complaints For The Quarter Ended June 2022

No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ch Venkat RameshDesignation :- Company Secretary and Compliance Officer
04-07-2022
Next Page
Close

Let's Open Free Demat Account